Acute myeloid leukemia (AML) is a hard-to-treat cancer in which certain leukemia stem/progenitor cells (LSPCs) hide in the bone marrow and resist treatment. Researchers led by Michael Andreeff, M.D., Ph.D., and Yuki Nishida, M.D., Ph.D., examined valemetostat, which targets EZH1 and EZH2 – proteins linked to keeping these LSPCs dormant. While valemetostat alone does not directly fight leukemia, it can wake up hidden LSPCs, making them vulnerable to chemotherapy. In lab models, researchers demonstrated that valemetostat improved the activity...
A newly published study by researchers at the University of Texas Medical Branch offers fresh insights into a critical public health concern: why Americans live shorter lives compared to people in other wealthy nations. The study was led by Dr. Neil Mehta, Professor of Epidemiology and Associate Dean of Research at the School of Public and Population Health, and Dr. Octavio Bramajo, a postdoctoral fellow at UTMB’s Sealy Center on Aging. Their research investigates...